SUR1-TRPM4 inhibition, most often with glibenclamide, reduced cerebral edema, BBB permeability, hemorrhage progression, and functional deficits in multiple independent studies of preclinical TBI models [29,30,32,33,35,43,44,45,112]. The gene discussed is TRPM4; the disease is hemorrhage.